Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: Evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy

Neuroscience

Volumn 95, Issue 1, 1999, Pages 89-95

  Lee, W T ^a   Shen, Y Z ^a   Chang, C ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

3 nitropropionic acid; Glutamate; Magnetic resonance spectroscopy; Mitochondrial dysfunction; N acetylaspartate (NAA); T2 maps

Indexed keywords

3 NITROPROPIONIC ACID; CREATININE; DIZOCILPINE; LAMOTRIGINE; N ACETYLASPARTIC ACID; 3-NITROPROPIONIC ACID; ASPARTIC ACID; CHOLINE; CREATINE; DIZOCILPINE MALEATE; DRUG DERIVATIVE; N-ACETYLASPARTATE; NEUROPROTECTIVE AGENT; NITRO DERIVATIVE; PROPIONIC ACID DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CORPUS STRIATUM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ASPARTIC ACID; BEHAVIOR, ANIMAL; BRAIN; CHOLINE; CORPUS STRIATUM; CREATINE; DIZOCILPINE MALEATE; HIPPOCAMPUS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; TRIAZINES;

EID: 0033629142     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)00410-8     Document Type: Article

References (69)

1. Alexi T., Hughes P.E., Knusel B., Tobin A.J. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALA/cByJ mice. Expl Neurol. 153:1998;74-93.
2. Allen H.L., Iversen L.L. Phencyclidine, dizocilpine and cerebrocortical neurons. Science. 274:1990;221.
3. Ankarcrona M., Dypbukt J.M., Bonfoco E., Zhivotovsky B., Orrenius S., Lipton S.A., Nicotera P. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 15:1995;961-973.
4. 1H NMR: a new tool for studying in situ brain metabolism in the living animals. Fedn Eur. biochem. Socs Lett. 264:1990;198-202.
5. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:1992;119-130.
6. Beal M.F. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16:1993;125-131.
7. Beal M.F., Brouillet E., Jenkins B.G., Henshaw R., Rosen B., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
8. Behrens M.I., Koh J., Canzoniero L.M.T., Sensi S.L., Csernansky C.A., Choi D.W. 3-Nitropropionic acid induces apoptosis in cultured striatal and cortical neurons. NeuroReport. 6:1995;545-548.
9. Benveniste H., Cofer G.P., Piantadosi C.A., Davis J.N., Johnson G.A. Quantitative proton magnetic resonance in focal cerebral ischemia in rat brain. Stroke. 22:1991;259-268.
10. Borlongan C.V., Koutouzis T.K., Sanberg P.R. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci. Biobehav. Rev. 21:1997;289-293.
11. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Beal M.F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60:1993;356-359.
12. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. natn. Acad. Sci. U.S.A. 92:1995;7105-7109.
13. Brouillet E., Guyot M.C., Mittoux V., Altairac S., Conde F., Palfi S., Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70:1998;794-805.
14. Brownell A.L., Jenkins B.G., Elmaleh D.R., Deacon T.W., Spealman R.D., Isacson O. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nature Med. 4:1998;1308-1312.
15. Castillo M., Kwock L., Mukherji S. Clinical application of proton MR spectroscopy. Am. J. Neuroradiol. 17:1996;1-15.
16. Chapman A.G., Durmuller N., Lee G.J., Meldrum B.S. Excitotoxicity of NMDA and kainic acid is modulated by nigrostriatal dopaminergic fibers. Neurosci. Lett. 107:1989;256-260.
17. Choi D.W. Cerebral hypoxia: some new approaches and unanswered questions. J. Neurosci. 10:1990;2493-2501.
18. Chyi T., Chang C. Temporal evolution of 3-nitropropionic acid-induced neurodegeneration in the rat brain by T2-weighted, diffusion-weighted, and perfusion magnetic resonance imaging. Neuroscience. 92:1999;1035-1041.
19. Coles C.J., Edmondson D.E., Singer T.P. Inactivation of succinate dehydrogenase by 3-nitropropionate. J. biol. Chem. 254:1979;5161-5167.
20. Cousin J.P. Clinical MR spectroscopy: fundamentals, current applications, and future potential. Am. J. Roentgen. 164:1995;1337-1347.
21. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
22. Crumrine R.C., Bergstrand A., Cooper A.T., Faison W.L., Cooper B.R. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke. 28:1997;2230-2237.
23. Filloux F., Wamsley J.K. Dopaminergic modulation of excitotoxicity in rat striatum: evidence from nigrostriatal lesions. Synapse. 8:1991;281-288.
24. Fix A.S., Horn J.W., Wightman K.A., Johnson C.A., Long G.G., Storts R.W., Farber N., Wozniak D.F., Olney J.W. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Expl Neurol. 123:1994;204-215.
25. Fix A.S., Wightman K.A., O'Callaghan J.P. Reactive gliosis induced by MK-801 in the rat posterior cingulate/retroplenial cortex: GFAP evaluation by sandwich ELISA and immunocytochemistry. Neurotoxicology. 16:1995;229-239.
26. Frahm J. and Hanefeld F. (1997) Localized proton magnetic resonance spectroscopy of brain disorders in childhood. In Magnetic Resonance Spectroscopy and Imaging in Neurochemistry (ed. Bachelard H.), Vol. 8, Advances in Neurochemistry, pp. 329-402. Plenum, New York.
27. Friede R. Histochemical investigations on succinic dehydrogenase in the central nervous system - V. J. Neurochem. 6:1961;190-199.
28. Greenamyre J.T., Olsen J.M.M., Penney J.B., Young A.B. Autoradiographic characterization of N-methyl-D-aspartate-, quisqualate- and kainate-sensitive glutamate binding sites. J. Pharmac. exp. Ther. 233:1985;254-263.
29. Gu M., Cooper J.M., Gash M., Mann V.M., Javoy-Agid F., Scapira A.H.V. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39:1996;385-389.
30. 1H nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience. 69:1995;1095-1101.
31. Guyot M.C., Hantraye P., Dolan R., Palfi S., Maziere N., Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience. 79:1997;45-56.
32. Hamilton B.F., Gould D.H. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta neuropath. 72:1987;286-297.
33. Henneberry R.C., Novelli A., Cox J.A., Lysko P.G. Neurotoxicity at the N-methyl-D-aspartate receptor in enregy-compromised neurons. Ann. N.Y. Acad. Sci. 568:1989;225-233.
34. 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology. 50:1998;1033-1040.
35. Ishii H., Arai T., Morikawa S., Inubushi T., Tooyama I., kimura H., Mori K. Evaluation of focal cerebral ischemia in rats by magnetic resonance imaging and immunohistochemical analyses. J. cerebr. Blood Flow Metab. 18:1998;931-934.
36. Jenkins B.G., Brouillet E., Chen Y.C.I., Storey E., Schulz J.B., Kirschner P., Beal M.F., Rosen B.R. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J. cerebr. Blood Flow Metab. 16:1996;450-461.
37. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology. 50:1998;1357-1365.
38. Kageyama G.H., Wong-Riley M.T.T. Histochemical localization of cytochrome oxidase in the hippocampus: correlation with specific neuronal types and afferent pathway. Neuroscience. 7:1982;2337-2361.
39. Leach M.J., Baxter M.G., Critchley M.A. Neurochemical and behavioral aspects of lamotrigine. Epilepsia. 32:(Suppl.):1991;S4-8.
40. Ludolph A.C., Seelig M.O., Ludolph A., Novitt P., Allen C.N., Spencer P.S., Sabri M.I. 3-Nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical explants. Neurodegeneration. 1:1992;21-28.
41. Macdonald R.L., Greenfield L.J. Mechanisms of action of new antiepileptic drugs. Curr. Opin. Neurol. 10:1997;121-128.
42. Maragos W.F., Jakel R.J., Pang Z., Geddes J.W. 6-Hydroxydopamine injections into the nitrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Expl Neurol. 154:1998;637-644.
43. Matthews P.M., Andermann F., Silver K., Karpati G., Arnold D.L. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology. 43:1993;2484-2490.
44. Messam C.A., Greene J.G., Greenamyre J.T., Robinson M.B. Intrastriatal injections of the succinate dehydrogenase inhibitor, malonate, cause a rise in extracellular amino acids that is blocked by MK-801. Brain Res. 684:1995;221-224.
45. 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 58:1996;1929-1935.
46. 3H] glutamate-binding sites in rat brain. J. Neurosci. 5:1985;2909-2919.
47. Nishino H., Shimano Y., Kumazaki M., Sakurai T. Chronically administered 3-nitropropionic acid induced striatal lesions attributed to dysfunction of the blood-brain barrier. Neurosci. Lett. 186:1995;161-164.
48. Nishino H., Kumazaki M., Fukuda A., Fujimoto I., Shimano Y., Hida H., Sakurai T., Deshpande S.B., Shimizu H., Morikawa S., Inubushi T. Acute 3-nitroproprionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: involvement of dopamine toxicity. Neurosci. Res. 27:1997;343-355.
49. Novelli A., Reilly A.J., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via N-methyl-D-aspartate receptor when intracellular enregy levels are reduced. Brain Res. 451:1988;205-212.
50. Pang Z., Umberger G.H., Geddes J.W. Neuronal loss and cytoskeletal disruption following intrahippocampal administration of the metabolic inhibitor malonate: lack of protectiion by MK-801. J. Neurochem. 66:1996;474-484.
51. Pang Z., Geddes J.W. Mechanisms of cell death induced by mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J. Neurosci. 17:1997;3064-3073.
52. Pulsinelli W., Sarokin A., Buchan A. Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia. Prog. Brain Res. 96:1993;125-135.
53. Raboisson P., Flood K., Lehmann A., Berge O.G. MK-801 neurotoxicity in the guinea pig cerebral cortex: susceptibility and regional differences compared with the rat. J. Neurosci. Res. 49:1997;364-371.
54. 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed. 4:1991;59-63.
55. Sato S., Gobbel G.T., Honkaniemi J., Li Y., Kondo T., Murakami K., Sato M., Copin J.C., Chan P.H. Apoptosis in the striatum of rats following intraperitoneal injection of 3-nitropropionic acid. Brain Res. 745:1997;343-347.
56. Sauer D., Allegrini P.R., Thedinga K.H., Massieu L., Amacker H. Evaluation of quinolinic acid induced excitotoxic neurodegeneration in rat striatum by quantitative magnetic resonance imaging in vivo. J. Neurosci. Meth. 42:1992;69-74.
57. Schapira A.H.V. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr. Opin. Neurol. 9:1996;260-264.
58. Schultz J.B., Beal M.F. Mitochondrial dysfunction in movement disorders. Curr. Opin. Neurol. 7:1994;333-339.
59. Schulz J.B., Mattews R.T., Henshaw D.R., Beal M.F. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 71:1996;1043-1048.
60. Simpson J.R., Isacson O. Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Expl Neurol. 121:1993;57-64.
61. 2+ currents in cortical neurons: functional implications. Eur. J. Pharmac. 307:1996;113-116.
62. 1H nuclear magnetic resonance spectroscopy and biochemical characterization. Neuroscience. 79:1997;819-826.
63. Urejnak J., Williams S.R., Gadian D.G., Noble M. Proton nuclear magnetic resonance unambiguously identifies neural cell types. J. Neurosci. 13:1993;981-989.
64. Wang S.J., Huang C.C., Hsu K.S., Tsai J.J., Gean P.W. Inhibition of N-type calcium currents in lamotrigine in rat amygdalar neurons. NeuroReport. 7:1996;3037-3040.
65. Wang S.J., Tsai J.J., Gean P.W. Lamotrigine inhibits depolarization-evoked Ca influx in dissociated amygdala neurons. Synapse. 29:1998;355-362.
66. Wang Z., Zimmerman R.A., Sauter R. Proton MR spectroscopy of the brain: clinically useful information obtained in assessing CNS diseases in children. Am. J. Roentgen. 167:1996;191-199.
67. Zeevalk G.D., Nicklas W.J. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J. Pharmac. exp. Ther. 253:1990;1285-1292.
68. Zeevalk G.D., Nicklas W.J. Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. J. Pharmac. exp. Ther. 257:1991;870-878.
69. Zhang X., Boulton A.A., Zou D.M., Yu P.H. MK-801 induces apoptotic neuronal death in the rat retroplenial cortex: prevention by cycloheximide and r(-)-2-hexyl-n-methylpropargylamine. J. Neurosci. Res. 46:1996;82-89.